Isabel Ruehl is a former editorial intern at Spectrum. She recently graduated from Columbia Journalism School and, before that, earned an M.Phil. in Health, Medicine and Society from Cambridge University in the United Kingdom.
Isabel Ruehl
Former news intern
Spectrum
From this contributor
‘Science working as it should’: Autism blood signature study earns open post-publication review
Shortly after the study’s publication, experts critiqued it on PubPeer and other online platforms.
‘Science working as it should’: Autism blood signature study earns open post-publication review
By
Isabel Ruehl
10 January 2023 | 5 min read
Whole-genome trove ties new genes, variants to autism
A massive update to the MSSNG dataset gives qualified researchers ready access to explore autism’s genetic architecture on a cloud-based platform.
Whole-genome trove ties new genes, variants to autism
By
Isabel Ruehl
12 December 2022 | 4 min read
Autism incidence in England varies by ethnicity, class, location
High rates of autism are linked to lower socioeconomic status and minority ethnic groups, according to the largest-ever autism incidence study.
Autism incidence in England varies by ethnicity, class, location
By
Isabel Ruehl
6 December 2022 | 5 min read
‘Assembloids’ lay bare autism-linked genes that hamper neuron development
The model enables the study of autism-linked genes at the earliest stages of neural development.
‘Assembloids’ lay bare autism-linked genes that hamper neuron development
By
Isabel Ruehl
30 November 2022 | 4 min read
Lab-grown ‘embryoids’ offer new window into gene-trait relationships
The developmental models have advantages over natural embryos and other synthetic models, such as organoids, but present technical and ethical challenges.
Lab-grown ‘embryoids’ offer new window into gene-trait relationships
By
Isabel Ruehl
26 October 2022 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read